Skip to main content

Table 1 Patients and tumour characteristics for 199 lung cancer patients scheduled for treatment with erlotinib

From: Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

  Number Percent
Gender   
Male 101 51
Female 98 49
Ethnicity   
Asian 1 <1
Caucasian 198 >99
Smoking history   
Current smoker 64 32
Former smoker 118 59
Never smoker 17 9
ECOG performance status*   
0 26 13
1 99 49
2 63 32
3 11 6
Tumour type   
Adenocarcinoma 190 95
Adenosquamous carcinoma 9 5
Tumour stage   
IIA + IIB 2 1
IIIA + IIIB 29 15
IV 168 84
Erlotinib therapy   
First-line 22 11
Second-line 156 78
Third-line 16 8
Fourth-line 5 3
Age (years, mean (range)) 64 (33–87)  
  1. *Eastern Cooperative Oncology Group scale to assess how the disease affects the daily living abilities of the patient.